Skip to main content

Table 3 Cost parameters and corresponding values

From: Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore

Parameter

Cost per episode1, mean ± SD (95% CI)

2020 US$

TAVI mean episodic charge without AEs

54,301

SAVR mean episodic charge without AEs

26,109

Follow-up care after procedure

372

Disabling or major stroke

14,243 ± 11,914 (4252 to 47,508)

Neurologist outpatient visit

243

Rehospitalisation

6120 ± 9280 (667 to 26,476)

MI

13,736 ± 13,143 (1436 to 44,309)

Major vascular complication

13,773 ± 13,858 (3486 to 54,403)

Life-threatening, disabling, or major bleeding

8652 ± 7524 (2408 to 30,786)

Endocarditis

26,952 ± 29,945 (1813 to 114,305)

AKI

6203 ± 8445 (711 to 28,414)

New PPI

13,384 ± 8805 (5856 to 34,942)

TIA

2842 ± 2213 (749 to 7819)

Atrial fibrillation

5152 ± 8535 (597 to 25,330)

Paravalvular aortic regurgitation

22,231 ± 20,436 (831 to 69,572)

  1. Abbreviations: AEs adverse events; AKI acute kidney injury, CI confidence interval, MI myocardial infarction, PPI permanent pacemaker implantation, SAVR surgical aortic valve replacement, SD standard deviation, TAVI transcatheter aortic valve implantation
  2. Note: 1. The above costs were retrieved from the Casemix and Subvention System, which contains inpatient, day surgery episodic data or specialist outpatient visit data from public healthcare institutions (PHIs) for subvention purpose. It contains information on patient demographics, episode or visit details including ward class (admitted/discharged), subsidy status (i.e. subsidised/private), length of stay, cost (i.e. total charge, total bill), and clinical data such as diagnosis and procedure codes
  3. 2. More details on Australian Classification of Health Interventions (ACHI) and International Classification of Diseases (ICD)-10 codes and methods used are in Additional materials file 2